TC BioPharm Announces Pricing for $4 Million Underwritten Public Offering | New

Edinburgh, Scotland, June 2, 2022 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical-stage biotechnology company developing gamma-delta T cell therapies allogeneic cancer drugs, today announced the price of an underwritten public offering of 10,000,000 American Depositary Shares (the “ADSs”), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for total gross proceeds of $4 million, before deducting subscription discounts and commissions and other offering costs. In addition, the Company has granted subscribers a 45-day option to purchase up to an additional 1,500,000 ADSs at the public offering price per share, less underwriting discounts and fees, to cover over-allotments, if any. .

The offering is expected to close on or about June 7, 2022subject to satisfaction of customary closing conditions.

EF Hutton, a division of Benchmark Investments, LLC, is acting as sole bookrunner for the offering.

A registration statement on Form F-1 (File No. 333-265159) has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective on June [2]2022. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at Electronic copies of the final prospectus relating to this offering, when available, may be obtained from EF Hutton, a division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, Attention: Syndicate Department, or by email at or by phone at (212) 404-7002.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, and there will be no sale of such securities in any state or jurisdiction in which a such offer, solicitation or sale would be unlawful. prior to registration or qualification under the securities laws of any such state or territory.

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are natural immune cells that embody properties of the innate and adaptive immune systems and can inherently differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in unmodified and CAR-modified gamma delta T cells to effectively identify, target and eradicate liquid and solid cancer tumors.

TC BioPharm is the leader in the development of gamma-delta T cell therapies and the first company to conduct Phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T-cell product line – Phase 2b/3 pivotal trial for OmnImmune® in the treatment of acute myeloid leukemia and phase 1 trial for ImmuniStim in the treatment of Covid patients using the Company’s proprietary allogeneic CryoTC technology to supply frozen products to clinics worldwide. TC BioPharm also maintains a strong pipeline for future indications in solid tumors, as well as a significant intellectual property/patent portfolio in the use of CARs with gamma delta t cells and has its own manufacturing facility to maintain controls. cost and product quality.

Forward-looking statements

This press release may contain forward-looking statements relating to future events. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. Reference to the TC BioPharm website has been provided for convenience, and information contained on that website is not incorporated by reference into this press release.

Show original content to download multimedia:


About Barbara J. Ross

Check Also

Nisun discloses use of proceeds from underwritten public offering of approximately $77 million and invests approximately $32 million in 2 subsidiaries

Nisun International Enterprise Development Group Co.,Ltd NSIN announcement updates on its use of proceeds from …